The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study
Open accessAbstract
OBJECTIVE: Atypical (second-generation) antipsychotics are considered standard treatment for children and adolescents with early-onset schizophrenia and schizoaffective disorder. However, the superiority of second-generation antipsychotics over first-generation antipsychotics has not been demonstrated. This study compared the efficacy and safety of two second-generation antipsychotics (olanzapine and risperidone) with a first-generation antipsychotic (molindone) in the treatment of early-onset schizophrenia and schizoaffective disorder. METHOD: This double-blind multisite trial randomly assigned pediatric patients with early-onset schizophrenia and schizoaffective disorder to treatment with either olanzapine (2.5-20 mg/day), risperidone (0.5-6 mg/day), or molindone (10-140 mg/day, plus 1 mg/day of benztropine) for 8 weeks. The primary outcome was response to treatment, defined as a Clinical Global Impression (CGI) improvement score of 1 or 2 and >or=20% reduction in Positive and Negative Syndrome Scale (PANSS) total score after 8 weeks of treatment. RESULTS: In total, 119 youth were randomly assigned to treatment. Of these subjects, 116 received at least one dose of treatment and thus were available for analysis. No significant differences were found among treatment groups in response rates (molindone: 50%; olanzapine: 34%; risperidone: 46%) or magnitude of symptom reduction. Olanzapine and risperidone were associated with significantly greater weight gain. Olanzapine showed the greatest risk of weight gain and significant increases in fasting cholesterol, low density lipoprotein, insulin, and liver transaminase levels. Molindone led to more self-reports of akathisia. CONCLUSIONS: Risperidone and olanzapine did not demonstrate superior efficacy over molindone for treating early-onset schizophrenia and schizoaffective disorder. Adverse effects were frequent but differed among medications. The results question the nearly exclusive use of second-generation antipsychotics to treat early-onset schizophrenia and schizoaffective disorder. The safety findings related to weight gain and metabolic problems raise important public health concerns, given the widespread use of second-generation antipsychotics in youth for nonpsychotic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Self-citationA RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Williams, C. L., Hayman, L. L., Daniels, S. R., Robinson, T. N., Steinberger, J., Paridon, S., & Bazzarre, T. (2002) · Circulation · doi:10.1161/01.cir.0000019555.61092.9e · Cited by 774
Mathur, R. (2004) · Drug Screening Methods · doi:10.5005/jp/books/10243_6 · Cited by 665
National Trends in the Outpatient Treatment of Children and Adolescents With Antipsychotic Drugs
Olfson, M., Blanco, C., Liu, L., Moreno, C., & Laje, G. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.679 · Cited by 591
Time Course and Biologic Correlates of Treatment Response in First-Episode Schizophrenia
Lieberman, J. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820170047006 · Cited by 442
Self-citationChildhood-Onset Schizophrenia: A Double-blind Clozapine-Haloperidol Comparison
Kumra, S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830120020005 · Cited by 410
Lieberman, J. A., Tollefson, G., Tohen, M., Green, A. I., Gur, R. E., Kahn, R., McEvoy, J., Perkins, D., Sharma, T., Zipursky, R., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1396 · Cited by 404
Self-citationPractice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia
McClellan, J., & Stock, S. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.02.008 · Cited by 361
Self-citationRisperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
Schooler, N., Rabinowitz, J., Davidson, M., Emsley, R., Harvey, P. D., Kopala, L., McGorry, P. D., Van Hove, I., Eerdekens, M., Swyzen, W., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.947 · Cited by 348
WERRY, J. S., MCCLELLAN, J. M., & CHARD, L. (1991) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199105000-00017 · Cited by 344
Self-citationChildhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison
Shaw, P., Sporn, A., Gogtay, N., Overman, G. P., Greenstein, D., Gochman, P., Tossell, J. W., Lenane, M., & Rapoport, J. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.721 · Cited by 225
Kumra, S., Kranzler, H., Gerbino-Rosen, G., Kester, H. M., DeThomas, C., Kafantaris, V., Correll, C. U., & Kane, J. M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.043 · Cited by 223
Initial Anticholinergic Prophylaxis for Neuroleptic-Induced Extrapyramidal Syndromes
Keepers, G. A. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790090075012 · Cited by 216
Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis
Sanger, T. M., Lieberman, J. A., Tohen, M., Grundy, S., Beasley, Jr., & Tollefson, G. D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.79 · Cited by 215
Self-citationPractice Parameters for the Assessment and Treatment of Children and Adolescents with Schizophrenia
McClellan, J., & Werry, J. (1994) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199406000-00002 · Cited by 197
Self-citationAge at onset and gender of schizophrenic patients in relation to neuroleptic resistance
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.475 · Cited by 184
Risperidone in the Treatment of First-Episode Psychotic Patients: A Double-Blind Multicenter Study
Emsley, R. A., & Risperidone Working Group (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033413 · Cited by 180
Early Prediction of Antipsychotic Response in Schizophrenia
Correll, C. U., Malhotra, A. K., Kaushik, S., McMeniman, M., & Kane, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.11.2063 · Cited by 169
Time Course for Antipsychotic Treatment Response in First-Episode Schizophrenia
Emsley, R., Rabinowitz, J., & Medori, R. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.743 · Cited by 162
KINON, B., CHEN, L., ASCHERSVANUM, H., STAUFFER, V, KOLLACKWALKER, S., SNIADECKI, J., & KANE, J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.02.021 · Cited by 162
Crespo-Facorro, B., Pérez-Iglesias, R., Ramirez-Bonilla, M., Martínez-García, O., LLorca, J., & Vázquez-Barquero, J. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1004 · Cited by 159
Early Prediction of Antipsychotic Nonresponse Among Patients With Schizophrenia
Leucht, S., Busch, R. M., Kissling, W., & Kane, J. M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0301 · Cited by 143
Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia
McClellan, J., & WERRY, J. S. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200107001-00002 · Cited by 141
Self-citationEarly-onset schizophrenia: A 15-year follow-up
Röpcke, B., & Eggers, C. (2005) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-005-0483-6 · Cited by 140
A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients.
Pool, D., Bloom, W., Mielke, D. H., Jj, R., & Dm, G. (1976) · PubMed · Cited by 120
Long-Term Course of Adolescent Schizophrenia
Fleischhaker, C. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi014 · Cited by 120
Children With Schizophrenia: Diagnosis, Phenomenology, and Pharmacotherapy
SPENCER, E. K., & Campbell, M. (1994) · Schizophrenia Bulletin · doi:10.1093/schbul/20.4.713 · Cited by 116
Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., ANDERSON, R., Zablotsky, B., WILLIAMS, E., McNamara, N., Jackson, J. A., Ritz, L., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31807083fd · Cited by 104
Self-citationRemission in First-Episode Psychosis
Emsley, R. A., Oosthuizen, P. P., Kidd, M., Koen, L., Niehaus, D. J. H., & Turner, H. J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1106 · Cited by 98
Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods
McCLELLAN, J., SIKICH, L., FINDLING, R. L., FRAZIER, J. A., VITIELLO, B., HLASTALA, S. A., WILLIAMS, E., AMBLER, D., HUNT-HARRISON, T., MALONEY, A. E., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3180691779 · Cited by 90 · cited 4×
“Concomitant treatments with anticholinergic agents, propranolol, and benzodiazepines were guided by algorithms (28).”
InfluentialSelf-citationForty-two-years later: the outcome of childhood-onset schizophrenia
Remschmidt, H., Martin, M., Fleischhaker, C., Theisen, F., Hennighausen, K., Gutenbrunner, C. M., & Schulz, E. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0553-z · Cited by 89
Early-Onset Psychotic Disorders: Course and Outcome Over a 2-Year Period
McClellan, J., MCCURRY, C., Snell, J. L., & DuBose, A. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199911000-00012 · Cited by 87
Self-citationPathophysiology of early onset schizophrenia
Kyriakopoulos, M., & Frangou, S. (2007) · International Review of Psychiatry · doi:10.1080/09540260701486258 · Cited by 82
A 1-Year Open-Label Trial of Olanzapine in School-Age Children with Schizophrenia
Ross, R. G., Novins, D. K., Farley, G. K., & Adler, L. E. (2003) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454603322572633 · Cited by 75
Optimizing Early Prediction for Antipsychotic Response in Schizophrenia
Chang, Y., Lane, H., Yang, K.-H., & Huang, C. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000246211.95905.8c · Cited by 67
A Revised Anchored Version of the BPRS-C for Childhood Psychiatric Disorders
Hughes, C. W., Rintelmann, J. W., Emslie, G. J., Lopez, M. A., & MacCabe, N. (2001) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454601750143500 · Cited by 61
Clozapine-Induced Neutropenia in Children: Management with Lithium Carbonate
Sporn, A. L., Gogtay, N., Ortiz‐Aguayo, R., Alfaro, C. L., Tossell, J. W., Lenane, M., Gochman, P., & Rapoport, J. L. (2003) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454603322572697 · Cited by 58
Cited by
Correll, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Deacon, B. J. (2013) · Clinical Psychology Review · doi:10.1016/j.cpr.2012.09.007 · Cited by 643
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Increasing off‐label use of antipsychotic medications in the United States, 1995–2008
Alexander, G. C., Gallagher, S. A., Mascola, A., Moloney, R. M., & Stafford, R. S. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2082 · Cited by 423
Metadata
- Authors
- Sikich, L., Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., Ritz, L., Ambler, D., Puglia, M., Maloney, A. E., Michael, E., De Jong, S., Slifka, K., Noyes, N., Hlastala, S., Pierson, L., McNamara, N. K., Delporto-Bedoya, D., Anderson, R., Hamer, R. M., & Lieberman, J. A.
- Venue
- American Journal of Psychiatry
- Published
- 2008-11
- Volume
- 165
- Issue
- 11
- Pages
- 1420-1431
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2097116748
- Cited by
- 478
- References
- 42
- FWCI
- 28.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.